MYQORZO was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical ...

Ischemic heart disease is the leading cause of disability and premature death worldwide. Chronic coronary syndrome (CCS), previously known as stable angina, is a progressive and chronic disease of the ...

Actor T.K. Carter's cause of death has been revealed, after the "Punky Brewster" actor died in January at his home in Duarte, ...

HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C.

Background Four ‘pillars’ of heart failure therapy have been shown to reduce morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF). Although the European ...

Cytokinetics received U.S. FDA approval for MYQORZO on December 19, 2025. The approval was based on the positive results from the pivotal Phase 3 clinical trial, SEQUOIA-HCM, published in the New ...

Background Recurrent mitral regurgitation (MR) remains a major limitation of mitral valve (MV) repair in patients with ...

Several observations from preclinical and short-term clinical studies support a role for sildenafil in the treatment of heart failure patients. The following discussion briefly considers each of these ...

Samsung is working on ways to detect Left Ventricular Systolic Dysfunction (LVSD) using the Galaxy Watch. It has also conducted trials and received approval from South Korea’s Ministry of Food and ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

LBBB is linked to electrical abnormalities, causing inefficient heart pumping, dilation, and systolic dysfunction. The study found LBBB associated with increased heart failure risk, surpassing other ...